TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consent of the patient or legal guardian.~* Men or women aged between 18 and 65.~* Diagnosis of acute low back pain with moderate to severe pain (Visual Analog Scale greater than 4 cm)~Exclusion Criteria:~* fracture confirmed by X-ray~* Diagnosis of infection, fever,~* Pregnancy, lactation;~* Diagnosis of fibromyalgia;~* Hypersensitivity to ketorolac tromethamine, any of the ingredients of the formula or other Nonsteroidal anti-inflammatory

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen (Type: ACTIVE_COMPARATOR): Every 8 hours for 4 days.
- Ketorolac Tromethamine (Type: EXPERIMENTAL): Every 8 hours for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 6-17 years of age~* Documented history of hypertension as defined in National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004)~* Must be ≥ 21.0 kg and ≤ 100.0 kg at randomization~* Able to safely wash out previous antihypertensive therapy for 1-2 weeks~Exclusion Criteria:~* Body weight of \< 21 kg (45 lbs) or \> 100 kg (220 lbs)~* Inability to discontinue prior antihypertensive medication as required during the washout period~* Any clinically significant abnormalities or clinically noteworthy abnormal laboratory values~* Renal artery stenosis~* Current diagnosis of heart failure (NYHA Class II-IV)~* msSBP ≥ 25% above the 95th percentile for age, gender, and height at Visit 2~* Second or third degree heart block with or without a pacemaker~* Atrial fibrillation or atrial flutter at Visit 1, or potentially life threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1~* Evidence of current symptomatic valvular disease~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren 2 mg/kg (Type: EXPERIMENTAL): Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
- Aliskiren 6 mg/kg (Type: EXPERIMENTAL): Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of nasopharyngeal squamous carcinoma~* EBV-LMP1 positive~* Signed Informed Consent Form~Exclusion Criteria:~* Abnormal laboratory results within 45 days prior to study entry~* Participation in any study involving an experimental drug or an experimental medical device in 30 days prior to study entry~* Current pregnancy~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DZ1 (Type: EXPERIMENTAL): DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
- Saline (Type: PLACEBO_COMPARATOR): Placebo group receives saline injection in combination with radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 18 and 66 years of age.~* Subjects previously enrolled in study A7281009 (NCT01620255) who have completed the 84 day (12 week) induction period.~Exclusion Criteria:~* Subjects that have completed Day 84 (Week 12) of study A7281009 but have experienced serious event(s) related to the investigational product, an unstable medical condition, or any other reason, in the opinion of the investigator, would preclude entry or participation in this study.~* Subjects who are taking any dose of Azathioprine (AZA), 6-mercaptopurine(6 MP) or Methotrexate (MTX).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- SHP647 75 mg (Type: EXPERIMENTAL): Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
- SHP647 225 mg (Type: EXPERIMENTAL): Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PrEP in Breastfeeding Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For infant's mother and father~* Able and willing to provide informed consent for the infant to participate in the study~* Of legal age ≥18 years to consent~For HIV-uninfected mother, in addition to the criteria noted immediately above:~* Willing to provide breast milk samples and breastfeed during the duration of the study 0-24 weeks postpartum~* Breastfeeding an infant~* HIV-uninfected based on negative HIV rapid tests, both at study screening and at the enrollment visit~* Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ≥60 mL/min~* Not infected with hepatitis B virus, as determined by a negative hepatitis B surface antigen test~* Not currently using PrEP~* Note: single mothers will be eligible to participate in this study. Where possible the father's permission was be obtained. When the father is unknown, incompetent, deceased, or not reasonably available, or when only the mother has the legal responsibility for the care and custody of the child, infant participation will be based on the mother's consent and documentation will be added to file.~For infant~* Infant born to eligible women (both male and female infants will be included)~* Age 0-24 weeks~* Otherwise infant has no serious infections or active clinically significant medical problems~Exclusion Criteria:~* Women breastfeeding more than one child~* Preterm babies or infants with low birth weight (i.e. ≤2000mg)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FTC-TDF (Type: OTHER): Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Psidii Guava's Extract For COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Confirmed positive COVID-19 mild and symptomless~* Aged 13 - 59 years~* Willing to take part in the study and sign an informed consent~Exclusion Criteria:~* Not willing to join the study~* History of allergy to the research drug (extract Psidii guava)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Extract Psidii guava (Type: EXPERIMENTAL): 2 Capsule of extract Psidii guava, three times daily
- Standard therapy (Type: ACTIVE_COMPARATOR): Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for the Treatment of Incomplete Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* If no ultrasound used:~  1. Past or present history of vaginal bleeding during pregnancy; and~ 2. Open cervical os.~* If ultrasound used:~  1. Past or present history of vaginal bleeding during pregnancy; and~ 2. Evidence of incomplete abortion with substantial debris in the uterus.~All women would have been advised to have surgical evacuation of the uterus if misoprostol was not available.~* Willing to provide contact information for purposes of follow-up.~  * In Tanzania: 18 years of age or over or parental permission~ * In Mozambique: 21 years of age or over or parental permission~ * In Moldova: 18 years of age or over~ * In Madagascar: 18 years of age or parental permission~ * In Vietnam: reproductive age~Exclusion Criteria:~* Contraindications to the study drug;~* Uterine size larger than 12 weeks L.M.P. at time of presentation for care.~* Signs of severe infection, defined as at least one of the following of:~  1. foul smelling discharge,~ 2. fever \> 39 degrees C ,~ 3. pulse \>110/min;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): treatment with 600mcg oral misoprostol
- 2 (Type: ACTIVE_COMPARATOR): treatment with 400mcg sublingual misoprostol
- 3 (Type: ACTIVE_COMPARATOR): treatment with Manual Vacuum Aspiration (MVA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy~* Have active Crohn's disease, defined as a baseline Crohn's Disease Activity Index (CDAI) score of \>= 220 and \<= 450~* Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the treatment of Crohn disease and did not respond initially (ie, primary nonresponse)~* Or responded initially but then lost response with continued therapy (ie, secondary nonresponse)~* Or were intolerant to the medication~* Have screening laboratory test results within protocol-specified parameters.~Exclusion Criteria:~* Patients who have had any kind of bowel resection within 6 months~* Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent~* Patients who have received infliximab, adalimumab or certolizumab pegol \< = 8 weeks before the first administration of study drug~* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug~* Patients with a history of or ongoing chronic or recurrent infectious disease~* Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: PLACEBO_COMPARATOR): Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
- 002 (Type: EXPERIMENTAL): Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
- 003 (Type: EXPERIMENTAL): Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg) 390 mg (weight \> 55 kg and \<= 85 kg) and 520 mg (weight \> 85 kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively~* A history of 3 or more joint bleeds during the last 12 months~Exclusion Criteria:~* Joint bleeding within 7 days prior to trial start~* Treatment for bleeds within the last 5 days prior to trial start~* Clinically relevant coagulation disorders other than congenital haemophilia A or B

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are male or female between the ages of 5 and 17 years, inclusive, at the time of the first dose of study medication, with a history of biopsy and endoscopy confirmed UC;~* have mildly-to-moderately active UC (either newly diagnosed or that has relapsed) as defined clinically by a Pediatric UC Activity Index (PUCAI) score 10 and 55, and, in the opinion of the Investigator, the patient does not require steroids;~* have baseline scores of at least 1 for both rectal bleeding (Streaks of blood with stool less than half of the time) and stool frequency (1-2 stools greater than normal per day) as defined by the TM-Mayo Score~Exclusion Criteria:~* have UC known to be confined to the rectum (isolated rectal proctitis);~* have a history of allergy or hypersensitivity to salicylates, aminosalicylates, or any component of the Asacol tablet;~* have a significant co-existing illness or other condition(s), including but not limited to cancer or significant organic or psychiatric disease on medical history or physical examination, that, in the judgment of the Investigator, contraindicate(s) administration of the study drug and/or any study procedures

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Low-Dose (Type: EXPERIMENTAL): 1.2 - 2.4 g/day Asacol dependent on body weight
- High-Dose (Type: EXPERIMENTAL): 2.0 - 4.8 g/day Asacol dependent on body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diminution of vision due to diabetic macular edema.~* CMT ≥ 250 µ.~* Willing to participate in the study.~Exclusion Criteria:~* Unwilling to participate in the study, 2)~* Ischemic RVO,~* previous laser treatment~* Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris,~* patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion,~* Cardiac co-morbidities result in significant hemodynamic changes, 7)Respiratory diseases need treatment with antibiotics,~* Suffering from other chronic diseases as diabetes,~* Patient with allergy from triamcinolone acetonide.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Formulated Posterior Sub Tenon Triamcinolone (Type: ACTIVE_COMPARATOR): None
- Posterior Sub Tenon Triamcinolone alone (Type: ACTIVE_COMPARATOR): None
- suprachoroidal Triamcinolone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia with acute exacerbation of illness~* The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.~Exclusion Criteria:~* Subjects with evidence or history of clinically significant uncontrolled medical illness~* Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.~* Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PF-02545920 5 mg (Type: EXPERIMENTAL): None
- PF-02545920 15 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Risperidone 3 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18~2. Active duty or Department of Defense (DoD) beneficiary~3. Diagnosed with rheumatoid arthritis meeting ACR/EULAR 2010 classification criteria and any one of the following:~   1. Patient does not want to be on rheumatologic medications~  2. Patient has contraindications to standard rheumatologic medications~  3. Patient has failed treatment or an incomplete response with standard rheumatologic medications~4. Women of childbearing age must have a negative pregnancy test and currently be on a reliable form of birth control~Exclusion Criteria:~1. Severe depression~2. Dementia, mental disability~3. Claustrophobia~4. Uncontrolled seizure disorder~5. Uncontrolled asthma/severe chronic obstructive pulmonary disease (COPD) with partial pressure of carbon dioxide (pCO2) \> 45 mmHg on arterial blood gas~6. Grade 4 congestive heart failure~7. Unstable angina~8. Chronic/acute otitis media/sinusitis~9. Major tympanic membrane trauma~10. Severe kyphoscoliosis~11. Prior chemotherapy with Bleomycin and evidence of deterioration in diffusion capacity of the lung for carbon monoxide (DLCO) after a single hyperbaric oxygen exposure~12. History of renal insufficiency or glomerular filtration rate (GFR)\< 30~13. Women that are currently pregnant or breast feeding or intend on becoming pregnant while enrolled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperbaric Oxygen (Type: EXPERIMENTAL): Hyperbaric Oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete